Charles River Laboratories Intl. Inc vs Newmont Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $287.3 (market cap $13.46B), while Newmont Corporation trades at $118.23 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 9.2× Charles River Laboratories Intl. Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NEM | |
|---|---|---|
Market Cap | $13.46B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $282.00 | $131.95 |
52-Week Low | $145.57 | $67.38 |
Enterprise Value | $16.30B | $120.09B |
Dividend Yield | — | 0.89% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Newmont Corporation (NEM) trades at $119.12, up 1.59% with strong technical momentum as it approaches resistance near $120. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.10 versus $2.05 forecast, continuing a trend of earnings outperformance. Revenue growth accelerated to $22.67 billion in 2025 with net income margin expanding to 33.36%. Recent news highlights resolution of Nevada disputes with Barrick Mining and strong gold price environment supporting miner profitability.
Outlook remains positive with analyst consensus price target of $133 representing 11.6% upside potential. Key opportunities include continued gold price strength and operational efficiency gains, while risks involve potential cost inflation and gold price volatility. With 76% analyst buy ratings and improving cash flow trends, NEM appears well-positioned for continued growth in the current commodity cycle.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →